Tailoring Treatment in Obstructive Lung Disease: Asthma, COPD, Asthma/COPD Overlap and Eosinophilic COPD
Obstructive lung disease exacts a huge global health burden with a high prevalence of both asthma and COPD in elderly patients.
Purpose of Review
This review is to update the general and elderly care physician on diagnosis and management of COPD and asthma and the recently established disease asthma/COPD overlap (ACO) and the particular challenges treating obstructive lung disease in elderly patients.
COPD pharmacology has changed considerably in the last decade with a dramatic increase in the utility of single and dual long-acting bronchodilators both for symptom and exacerbation attenuation. The emergence of ACO and the COPD phenotype eosinophilic COPD also appear to require nuanced therapeutic approaches. There is also a strong emphasis now on screening and treating comorbid conditions in COPD. In asthma the emergence of tailored therapy for different severe asthma phenotypes is also discussed.
Obstructive lung diseases are very common in elderly patients and both diagnosis and treatment of these conditions is more challenging than in younger patients.
KeywordsAsthma COPD Exacerbation Asthma/COPD overlap Eosinophilic COPD
Compliance with Ethical Standards
Conflict of Interest
Robert Rutherford, Andrew Scott and Joseph Walsh declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Asthma GIf. Global Strategy for asthma management and prevention, 2018. 2018.Google Scholar
- 5.Disease GIfCOL. Global STRATEGY for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). 2018.Google Scholar
- 6.Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–42. https://doi.org/10.1016/s2213-2600(15)00106-x.CrossRefPubMedGoogle Scholar
- 7.Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013;187(9):1016–27. https://doi.org/10.1164/rccm.201303-0437ST.CrossRefPubMedGoogle Scholar
- 8.Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161(1):309–29. https://doi.org/10.1164/ajrccm.161.1.ats11-99.CrossRefPubMedGoogle Scholar
- 11.Network BTSSIG. SIGN 153 British guideline on the management of asthma. 2016.Google Scholar
- 12.Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):Cd003559. https://doi.org/10.1002/14651858.CD003559.pub4
- 13.Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16. https://doi.org/10.1111/j.1398-9995.2004.00772.x.CrossRefPubMedGoogle Scholar
- 14.NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 278. Omalizumab for treating severe persistent allergic asthma. 2013.Google Scholar
- 15.• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207. https://doi.org/10.1056/NEJMoa1403290. This was a tremendous breakthrough in severe asthma care as previously only atopic subjects could benefit from targeted therapy. CrossRefPubMedGoogle Scholar
- 17.Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66. https://doi.org/10.1016/s2213-2600(15)00042-9.CrossRefPubMedGoogle Scholar
- 18.Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–90. https://doi.org/10.1016/s2213-2600(14)70201-2.CrossRefPubMedGoogle Scholar
- 19.NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 479. Reslizumab for treating severe eosinophilic asthma. 2017.Google Scholar
- 20.NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 431. Mepolizumab for treating severe refractory eosinophilic asthma. 2017.Google Scholar
- 27.Labonte LE, Tan WC, Li PZ, Mancino P, Aaron SD, Benedetti A, et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD Study. Am J Respir Crit Care Med. 2016;194(3):285–98. https://doi.org/10.1164/rccm.201509-1795OC.CrossRefPubMedGoogle Scholar
- 28.Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2008;(2):Cd000165. https://doi.org/10.1002/14651858.CD000165.pub3.
- 29.Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61(9):772–8. https://doi.org/10.1136/thx.2006.060145.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Katajisto M, Koskela J, Lindqvist A, Kilpeläinen M, Laitinen T. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations. Respir Med. 109(10):1320–5. https://doi.org/10.1016/j.rmed.2015.08.001.
- 31.Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, et al. An official American Thoracic Society/European Respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med. 2015;192(11):1373–86. https://doi.org/10.1164/rccm.201510-1966ST.CrossRefPubMedGoogle Scholar
- 40.•• Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34. https://doi.org/10.1056/NEJMoa1516385. This was a seminal paper in COPD care demonstrating greater symptom and exacerbation control with a LABA/ LAMA compared to ICS/LABA in exacerbating patients with an FEV1 <60% predicted. CrossRefPubMedGoogle Scholar
- 44.Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503–8. https://doi.org/10.1164/rccm.201402-0207OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet (London, England). 2015;385(9971):857–66. https://doi.org/10.1016/s0140-6736(14)62410-7.CrossRefGoogle Scholar
- 46.Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017;196(12):1535–43. https://doi.org/10.1164/rccm.201707-1327OC.CrossRefPubMedGoogle Scholar
- 47.Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA. 2015;313(9):936–48. https://doi.org/10.1001/jama.2015.1175.CrossRefPubMedGoogle Scholar
- 50.Anzueto A, Miravitlles M. Considerations for the correct diagnosis of chronic obstructive pulmonary disease and its management with bronchodilators. Chest. 2018; https://doi.org/10.1016/j.chest.2018.02.023.
- 54.Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–71. https://doi.org/10.1164/rccm.201104-0597OC.CrossRefPubMedGoogle Scholar
- 55.Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–74. https://doi.org/10.1164/rccm.201509-1869OC.CrossRefPubMedGoogle Scholar